Development of Saudi Arabia’s First SAP-Based Organoid 3D Platform

This project aims to develop the first self-assembly peptide (SAP)-based organoid 3D platform, focusing on drug screening, prognosis, signaling, and grafting studies. The project utilizes diverse formulations of SAP nanofibers, optimized with additional extracellular matrix (ECM) bio-functionalities, to recreate functional organoids derived from both healthy and cancerous patient tissues. Initially, 3D formulated models will be used to evaluate drug screening and cell growth. Validation of these models will be conducted through multi-omics data analysis. This innovative technology aims to enable the efficient and precise formation of 3D peptide scaffolds with encapsulated cells, laying the groundwork for the scaled-up fabrication of functional organoids.

The project focuses on colorectal cancer and hepatocellular carcinoma, two of the most prevalent cancers in Saudi Arabia, using genetic screening, drug testing, and studying cell growth studies in patient-derived organoids (PDOs). Specific objectives include optimizing and characterizing bioactive peptide formulations for organoid formation, establishing PDO lines, and developing in vitro models for colorectal and liver tissues using PDOs. Ultimately, this project seeks to enhance oncology precision medicine locally.